Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT07358130
Recruiting Not applicable

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy

NCT07358130 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Kaohsiung Medical University
Phase
Not applicable
Started
2025-10-21
Last updated
2026-01-22

Condition(s) studied

Helicobacter Pylori Infection

Investigational drug(s) / intervention(s)

vonoprazan, tripotassium dicitrate bismuthate, amoxicillinerabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole

vonoprazan, tripotassium dicitrate bismuthate, amoxicilline: bismuth-amoxicillin-vonoprazan triple therapy

rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole: bismuth-based quadruple therapy

Study summary

(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subjects with Helicobacter pylori infection Exclusion Criteria: 1. Subjects with known hypersensitivity to the study drug. 2. Subjects with a history of gastric surgery. 3. Subjects with severe liver cirrhosis or uremia. 4. Subjects with a history of malignancy within the past five years. 5. Pregnant or breastfeeding women. 6. Subjects currently receiving treatment with atazanavir sulfate or rilpivirine hydrochloride.

Primary outcome measure(s)

  • The rate of Helicobacter pylori eradication — 6 weeks after finishing study drugs
    evaluate eradication by 13C urea breath test
  • Evaluation of the safety of Helicobacter pylori eradication therapy — 14 days
    Drug-related adverse effects assessed by a standardized questionnaire

Trial sites (1)

FacilityCityRegionStatus
Kaohsiung Medical University Hospital Kaohsiung City Taiwan Recruiting

More Kaohsiung Medical University trials in Taiwan

DDK Acoustic Analysis and Swallowing Indicators Starting soon
Development of an Active Heat Dissipation Device Based on Thermoelectric Cooling Technology: Aiming to Improve Endurance Sports Performance Active, not recruiting
Effectiveness of an Online Interactive E-book in Enhancing Home Care Nurses' Knowledge, Perceived Barriers, and Self-efficacy in Home Pressure Injury Care Recruiting
The Immediate Effect of Applying Transcutaneous Electrical Nerve Stimulation (TENS) on Sympathetic Ganglion and Gastrocnemius for Popliteal Blood Flow Recruiting
Blood Flow Restriction Parameters and Lower Limb Function in Older Adults With Dynapenia Starting soon

Other trials for the same condition

The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication Enrolling by invitation
Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males Enrolling by invitation
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection Recruiting
Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection Recruiting
Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07358130 on ClinicalTrials.gov ↗ ← All trials in Taiwan